• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • Q&A
    • Videos
    • Comment
    • Analysis
    • People moves
    • In Profile
  •  
    Analysis
    • Videos
    • Q&A
    • Comment
    • In Profile
    • Podcast
    • Fundraising
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Portfolio management

3i-backed Ponroy buys Pasquali Healthcare

  • Alessia Argentieri
  • Alessia Argentieri
  • 01 April 2019
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

3i Group- and Cathay Capital-backed Ponroy Santé Group has acquired Italian pharmaceutical company Pasquali Healthcare.

Pasquali Healthcare CEO Costantino Pasquali will stay on with the business and lead the development of Ponroy in the Italian pharmacy channel.

Following this acquisition, Ponroy expects to add new product lines to its offering and strengthen its presence in Italy, where the group currently operates through a subsidiary distributing the Vitarmonyl and Biopha Nature brands.

3i invested in healthcare specialist Ponroy Santé in November 2016 together with Cathay Capital and the company's management. The GPs deployed a combined equity investment of €180m, comprising €150m from 3i and €30m from Cathay, while a debt package was provided by Natixis, BNP Paribas, Societe Generale, Bank of Ireland, ING and HSBC. The business reported EBITDA of €25m from €170m in sales at the time.

This is the third bolt-on made by Ponroy, following its acquisition of Monaco-based food supplements and opthalmic medicines laboratory Densmore in July 2018 and the purchase of Ersa, the owner of the Aragan and Synactifs brands, in September 2017.

According to a statement, with this latest acquisition Ponroy is now the third largest player in the French food supplement pharmacy channel and aims to replicate its business model across Europe with additional acquisitions.

Company
Founded in 1999 and headquartered in Florence, Pasquali Healthcare develops and commercialises over-the-counter drugs and medications for the Italian pharmacy market. The company markets its products under the Dermovitamina brand, which offers a wide portfolio of medications for skin disorders, and the Serenatural brand, which provides dietary and natural food supplements. Pasquali's products are sold through 7,000 pharmacies and several distributors. The company generated revenues of €23m in 2018. 

People
Ponroy Santé – Philippe Charrier (CEO, president).
Pasquali Healthcare – Costantino Pasquali (CEO).
3i Group – Rémi Carnimolla (partner, managing director); Gillaume Basquin (director).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Portfolio management
  • Southern Europe
  • Healthcare
  • 3i
  • Cathay Capital
  • France
  • Italy
  • Build-up
  • Buy-and-build

More on Portfolio management

NorthEdge sells Belfield Group's Usleep
NorthEdge sells Belfield Group's Usleep

Mattress producer is to be acquired by Vita Group, a portfolio company of Strategic Value Partners

  • Portfolio management
  • 28 September 2021
Synova's Mintec buys Kairos
Synova's Mintec buys Kairos

Synova acquired its stake in Mintec from the Peksa family in early 2018

  • Portfolio management
  • 11 August 2021
Clessidra's Botter bolts on Mondodelvino
Clessidra's Botter bolts on Mondodelvino

Combined group expects to reach revenues of €350m in 2020 and further expand its market share

  • Portfolio management
  • 26 April 2021
Bid Equity's Myneva bolts on Patronis, TTS
Bid Equity's Myneva bolts on Patronis, TTS

Social care and healthcare software platform is following a buy-and-build strategy

  • Portfolio management
  • 08 March 2021

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013